News Sentiment

INMB sentiment intelligence

INmune Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.94 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+14.1% over one week, +56.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

INmune Bio Says Study Shows Drug Candidate Reduced Alzheimer's-Related Brain Changes After Brain Injury

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 14.1% Price confirming higher
Trend fit Trend inactive 56.5% over four weeks
Fair value -67.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 30
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 9
TradingView 9
MT Newswires 4
Investing.com 3
simplywall.st 2
Yahoo! Finance Canada 1
Simply Wall Street 1

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 14
Balance sheet 3
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Investing.com Direct company coverage

INmune Bio publishes preclinical study on brain injury link to Alzheimer’s

INmune Bio Inc. announced the publication of a preclinical study in the Journal of Neurotrauma, revealing a link between traumatic brain injury and Alzheimer's disease. The study, funded by the Department of Defense, found that a single brain injury increased levels of Alzheimer'

Tone
Positive 73/100
Event
Market update
Published
15 Jul 2026 11:39
Source
Investing.com
Yahoo! Finance Canada Direct company coverage

INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

INmune Bio announced a preclinical study published in the Journal of Neurotrauma indicating that its drug candidate, XPro1595, prevents Alzheimer's pathology, memory loss, and pain induced by traumatic brain injury (TBI). The study found that XPro1595 neutralizes soluble TNF, a k

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 10:39
Source
Yahoo! Finance Canada
Simply Wall Street Direct company coverage

INmune Bio And 2 Other Promising Penny Stocks To Consider

This article highlights three promising "penny stocks" – INmune Bio (INMB), Identiv (INVE), and Vera Bradley (VRA) – as potential growth opportunities in a flat market. It details each company's financial health, recent developments, and market capitalization, emphasizing their p

Tone
Positive 63/100
Event
Market update
Published
13 Jul 2026 17:12
Source
Simply Wall Street
Market source Direct company coverage

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

INmune Bio will present positive Phase 2 imaging data for its XPro therapy in early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC). The data shows early treatment-related changes in white matter myelin integrity and cortical microstructure, sup

Tone
Positive 73/100
Event
Market update
Published
09 Jul 2026 17:10
Source
Market source
Stock Titan Direct company coverage

INmune Bio says XPro imaging data at AAIC show early Alzheimer’s brain changes

INmune Bio (NASDAQ: INMB) announced new Phase 2 imaging data for its drug XPro in early Alzheimer's disease, showing statistically significant changes in white matter myelin and concordant grey matter changes at Week 24. These findings, which support the biological activity of se

Tone
Positive 66/100
Event
Market update
Published
09 Jul 2026 11:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 INmune Bio Inc For: 7 July By Investing.com

This article reports on a Form 4 filing for INmune Bio Inc (INMB) on July 7, 2026. The company's stock showed a 4.20% increase at the time of publication. The piece also includes various financial market data and trending stocks.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Inmune Bio (INMB) CEO exercises 9,014 April 2024 warrants at $1.40

Inmune Bio, Inc.'s CEO, David J. Moss, exercised common stock purchase warrants to acquire 9,014 shares at $1.40 per share, increasing his direct holdings to 1,294,883 shares. This transaction was part of a warrant inducement offer where the maturity date for his remaining 50% of

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:13
Source
Stock Titan
Stock Titan Direct company coverage

INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term

INmune Bio's Chief Scientific Officer, Mark William Lowdell, exercised 7,211 common stock purchase warrants from April 2024, acquiring shares at $1.40 each and increasing his direct holdings to over 1.5 million shares. This transaction was part of a warrant inducement arrangement

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:13
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of INmune Bio Inc. – NASDAQ:INMB

This article provides a financial data point for INmune Bio Inc. (NASDAQ: INMB), specifically its "Price to book forward." The content is primarily a data page from TradingView, displaying financial metrics for the company.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 17:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of INmune Bio Inc. – NASDAQ:INMB

This article focuses on the enterprise value to revenue (forward) metric for INmune Bio Inc. (NASDAQ: INMB). It appears to be a financial data point or analysis provided by TradingView, likely indicating a measurement of the company's valuation relative to its projected revenue.

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 14:40
Source
TradingView
Ad-hoc-news.de Direct company coverage

Inmune Bio Inc outlines its immunotherapy focus as shares trade on Nasdaq

Inmune Bio Inc. (INMB) is a clinical-stage biotechnology company listed on Nasdaq, specializing in immunotherapies that modulate the innate immune system for treating cancer and neurodegenerative diseases. The company's strategy involves harnessing the body's natural defenses to

Tone
Positive 62/100
Event
Market update
Published
03 Jul 2026 12:39
Source
Ad-hoc-news.de
富途牛牛 Direct company coverage

Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference

This article provides a summary of INmune Bio's Q4 2025 Earnings Conference. It covers financial results, operational highlights, and potentially forward-looking statements discussed during the call.

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 09:40
Source
富途牛牛
Sahm Direct company coverage

Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth?

INmune Bio (NASDAQ:INMB) is an early-stage company that recorded no revenue last year and is still developing its business. The company had a cash runway of about 13 months as of March 2026, with a cash burn of US$20m against cash reserves of US$21m. While it reduced its cash bur

Tone
Negative 37/100
Event
Balance sheet
Published
03 Jul 2026 03:39
Source
Sahm
Market source Direct company coverage

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

INmune Bio, Inc. has submitted its CORDStrom™ platform patent application into the U.S. national phase, building on a favorable international written opinion. This move secures intellectual property for its next-generation mesenchymal stromal cell (MSC) platform, including Ebstro

Tone
Positive 95/100
Event
Market update
Published
01 Jul 2026 14:39
Source
Market source
Investing.com Direct company coverage

INmune Bio files U.S. patent for cell therapy platform

INmune Bio Inc. has submitted its CORDStrom platform patent application to the U.S. Patent and Trademark Office, advancing its intellectual property strategy for its mesenchymal stromal cell platform, which includes Ebstrocel for epidermolysis bullosa. The company's shares surged

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 11:40
Source
Investing.com
TradingView Direct company coverage

Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027

Inmune Bio (INMB) raised approximately $0.9 million by inducing the exercise of 647,112 warrants at $1.40 per share. Concurrently, the company extended the maturity date for the remaining 50% of its April 2024 warrants from June 30, 2026, to December 31, 2027. These agreements pr

Tone
Positive 63/100
Event
Market update
Published
01 Jul 2026 11:40
Source
TradingView
Stock Titan Direct company coverage

INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry

INmune Bio (NASDAQ: INMB) entered into an agreement with warrant holders to reduce the exercise price of certain April 2024 warrants from $1.95 to $1.40 per share, leading to immediate cash proceeds of $905,957 from the exercise of 647,112 warrants. In exchange, the maturity date

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 11:40
Source
Stock Titan
Stock Titan Direct company coverage

INmune Bio moves CORDStrom into U.S. patent review

INmune Bio (NASDAQ: INMB) has advanced its CORDStrom™ mesenchymal stromal cell platform patent application into the U.S. national phase, a strategic move following a favorable international PCT Written Opinion on patentability. This application, covering therapies like Ebstrocel

Tone
Positive 71/100
Event
Market update
Published
01 Jul 2026 10:40
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of INmune Bio Inc. – NASDAQ:INMB

This article provides the "Price to sales forward" metric for INmune Bio Inc. (NASDAQ: INMB). It is a financial data point indicating the company's valuation based on its forward sales. The data is presented within the context of TradingView's platform, which offers various finan

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 17:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB

This article provides a brief financial overview of INmune Bio Inc. (NASDAQ: INMB), focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of the data capture, with no trades reported. The content is primarily a data page from Trading

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 05:13
Source
TradingView
www.marketscreener.com Direct company coverage

INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Dynamic Index

INmune Bio Inc. (NasdaqCM: INMB) has been removed from the Russell 2000 Dynamic Index. This news was published on June 29, 2026, at 09:44 am EDT. The company, a clinical-stage biotechnology firm, specializes in developing treatments targeting the innate immune system.

Tone
Negative 38/100
Event
Market update
Published
29 Jun 2026 13:14
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBIT forward of INmune Bio Inc. – NASDAQ:INMB

The article presents financial information for INmune Bio Inc. (NASDAQ: INMB), specifically its enterprise value to EBIT forward. It notes that the market is closed, and there are no current trades for the stock. This appears to be a stub or partial financial data point provided

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 13:14
Source
TradingView
marketscreener.com Direct company coverage

INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Index

INmune Bio Inc. (NasdaqCM: INMB) has been removed from the Russell 2500 Index, among other Russell indices, but was added to the Russell Microcap Value Benchmark Index. The clinical-stage biotechnology company focuses on treatments targeting the innate immune system, with product

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 05:41
Source
marketscreener.com
TradingView Direct company coverage

Enterprise value to EBITDA forward of INmune Bio Inc. – NASDAQ:INMB

This article displays the "Enterprise value to EBITDA forward" for INmune Bio Inc. (NASDAQ: INMB) on TradingView. The financial data shows the period, value, change, and percentage change. The data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 03:09
Source
TradingView
TradingView Direct company coverage

INmune Bio, Inc. Actuals & Estimates (NASDAQ:INMB)

This article provides an overview of INmune Bio Inc. (NASDAQ: INMB) stock, covering its financials, analyst estimates, and performance data. It details the current stock price, historical highs and lows, market capitalization, earnings per share, and revenue figures. Additionally

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:39
Source
TradingView
Market source Direct company coverage

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

INmune Bio Inc. announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Pediatric Investigation Plan (PIP) for Ebstrocel™ (part of its CORDStrom™ platform) for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). This approval signif

Tone
Positive 74/100
Event
Regulatory and legal
Published
26 Jun 2026 06:00
Source
Market source